Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
Emory University
OHSU Knight Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Northside Hospital, Inc.